Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 18:10:553344.
doi: 10.3389/fonc.2020.553344. eCollection 2020.

Prognostic Value of MicroRNA-20b in Acute Myeloid Leukemia

Zhiheng Cheng  1   2   3 , Yifeng Dai  2 , Wenhui Huang  1   3 , Qingfu Zhong  1   3 , Pei Zhu  1   3 , Wenjuan Zhang  1   3 , Zhihua Wu  1   3 , Qing Lin  1   3 , Huoyan Zhu  1   3 , Longzhen Cui  4 , Tingting Qian  1   3 , Cong Deng  5 , Lin Fu  1   3   6   7 , Yan Liu  4 , Tiansheng Zeng  1   3
Affiliations

Prognostic Value of MicroRNA-20b in Acute Myeloid Leukemia

Zhiheng Cheng et al. Front Oncol. .

Abstract

Acute myeloid leukemia (AML) is a highly heterogeneous disease that requires fine-grained risk stratification for the best prognosis of patients. As a class of small non-coding RNAs with important biological functions, microRNAs play a crucial role in the pathogenesis of AML. To assess the prognostic impact of miR-20b on AML in the presence of other clinical and molecular factors, we screened 90 AML patients receiving chemotherapy only and 74 also undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) from the Cancer Genome Atlas (TCGA) database. In the chemotherapy-only group, high miR-20b expression subgroup had shorter event-free survival (EFS) and overall survival (OS, both P < 0.001); whereas, there were no significant differences in EFS and OS between high and low expression subgroups in the allo-HSCT group. Then we divided all patients into high and low expression groups based on median miR-20b expression level. In the high expression group, patients treated with allo-HSCT had longer EFS and OS than those with chemotherapy alone (both P < 0.01); however, there were no significant differences in EFS and OS between different treatment subgroups in the low expression group. Further analysis showed that miR-20b was negatively correlated with genes in "ribosome," "myeloid leukocyte mediated immunity," and "DNA replication" signaling pathways. ORAI2, the gene with the strongest correlation with miR-20b, also had significant prognostic value in patients undergoing chemotherapy but not in the allo-HSCT group. In conclusion, our findings suggest that high miR-20b expression is a poor prognostic indicator for AML, but allo-HSCT may override its prognostic impact.

Keywords: acute myeloid leukemia; allogeneic hematopoietic stem cell transplantation; chemotherapy; miR-20b; prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Kaplan-Meier curves of event-free survival (EFS) and overall survival (OS) in the chemotherapy-only and allo-HSCT groups. (A, B) In the chemotherapy-only group, high miR-20b expressers had shorter EFS and OS than low expressers. (C, D) In the allo-HSCT group, EFS and OS were not significantly different between high and low miR-20b expressers.
Figure 2
Figure 2
Kaplan-Meier curves of event-free survival (EFS) and overall survival (OS) in high and low miR-20b expression groups. (A, B) In low miR-20b expressers, EFS and OS were not significantly different between patients treated with chemotherapy-only and allo-HSCT. (C, D) In high miR-20b expressers, patients treated with allo-HSCT had longer EFS and OS than those underwent chemotherapy-only.
Figure 3
Figure 3
Biologic insight into miR-20b in AML. (A, B) Genes related to miR-20b and their pathway enrichment analysis. (C) Correlation analysis of miR-20b and ORAI2. (D–F) Survival analysis of ORAI2 in different groups.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. De Kouchkovsky I, Abdul-Hay M. ‘Acute myeloid leukemia: a comprehensive review and 2016 update’. Blood Cancer J (2016) 6:e441. 10.1038/bcj.2016.50 - DOI - PMC - PubMed
    1. Bullinger L, Döhner K, Döhner H. Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. J Clin Oncol (2017) 35:934–46. 10.1200/JCO.2016.71.2208 - DOI - PubMed
    1. Cheng Z, Dai Y, Zeng T, Liu Y, Cui L, Qian T, et al. . Upregulation of Glutamic-Oxaloacetic Transaminase 1 Predicts Poor Prognosis in Acute Myeloid Leukemia. Front Oncol (2020) 10:379. 10.3389/fonc.2020.00379 - DOI - PMC - PubMed
    1. Cheng Z, Dai Y, Pang Y, Jiao Y, Liu Y, Cui L, et al. . Up-regulation of DDIT4 predicts poor prognosis in acute myeloid leukaemia. J Cell Mol Med (2020) 24:1067–75. 10.1111/jcmm.14831 - DOI - PMC - PubMed
    1. Cheng Z, Dai Y, Pang Y, Jiao Y, Zhao H, Zhang Z, et al. . Enhanced expressions of FHL2 and iASPP predict poor prognosis in acute myeloid leukemia. Cancer Gene Ther (2019) 26:17–25. 10.1038/s41417-018-0027-0 - DOI - PubMed